DGAP-News: Xenikos B.V. to participate in 3PBio Forum technology transfer panel on September 29 at BIOSPAIN 2016

DGAP-News: Xenikos B.V. / Key word(s): Conference
Xenikos B.V. to participate in 3PBio Forum technology transfer panel on
September 29 at BIOSPAIN 2016

20.09.2016 / 10:00
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Xenikos B.V. to participate in 3PBio Forum technology transfer panel on
September 29 at BIOSPAIN 2016

Company to also meet with potential pharmaceutical partners for
immunotherapy T-GuardTM during BIOSPAIN

Nijmegen, the Netherlands, September 20, 2016 - Xenikos B.V., focused on
the development of innovative immunotherapies for the treatment of patients
suffering from serious immune diseases or rejection after transplantation,
announced today that management will participate in the upcoming BIOSPAIN
2016, being held September 28 - 30, 2016 in Bilbao, Spain.

CEO Ypke van Oosterhout will participate in the partnering event to meet
with potential pharmaceutical partners for Xenikos' product candidate, T-
GuardTM, which is in clinical development for the treatment of acute graft
versus host disease (GVHD).  Companies interested in meeting with Xenikos
at BIOSPAIN are asked to request a meeting through the event's partnering
online system or to contact Ypke van Oosterhout at
y.vanoosterhout@xenikos.com.

Maarten Frijlink, COO of Xenikos, will participate in the annual 3PBio
Forum. This year's session, "Good working relationships, communication and
confidence behind successful tech transfer," will address the fundamental
aspects of technology transfer to achieve the objectives and meet the
expectations of all parties involved in the development and manufacture of
biologics, from three perspectives: a drug developer, contract manufacturer
and technology provider.  The session is being led by 3P
Biopharmaceuticals, a leading European-based contract development and
manufacturing organization, and will include, in addition to Xenikos, two
other companies:  Ondek Pty Ltd, an Australian biotechnology company
developing natural immune modulatory products, and Sartorius, an
international leader in pharmaceutical equipment and technology. The forum
will take place during the second day of BIOSPAIN, on Thursday, September
29, 11.00-12.30 in room D of the BEC (Bilbao Exhibition Centre).

About BIOSPAIN
BIOSPAIN is the largest biotech event organized by a national bioindustry
association in Europe and one of the largest in the world based on the
number of one-on-one meetings (+3,300) and companies participating (+850).
BIOSPAIN is organized by ASEBIO, the Spanish Association of Biotech
Companies, and each event is co-organized by a local institution from the
host city/region. BIOSPAIN 2016 is being co-organized by the Basque
government through SPRI, the Basque Business Development Agency.

About T-Guard(TM)
T-Guard(TM) is currently in development by Xenikos for the treatment of
certain life-threatening immune conditions, such as transplant-related
rejection, graft versus host disease (GVHD), acute solid-organ rejection
and several severe autoimmune diseases. T-Guard(TM) consists of a
combination of two toxin-loaded anti-T-cell antibodies and shows promise as
a therapeutic tool for safely and swiftly resetting the body's immune
system in T-cell-mediated diseases. Once injected into the body, T-
Guard(TM) specifically identifies and eliminates adult T cells, with a
strong preference for the activated ones. The particular combination of
immunotoxins used to construct T-Guard(TM) was designed to provide a unique
blend of synergistic efficacy, narrow specificity and multiple, gentle
mechanisms of action. In preclinical testing, T-Guard(TM) was shown to be
highly effective in killing activated T cells and to act through apoptotic
(programmed cell death) mechanisms, which are associated with minimal side
effects. T-Guard's targeted action is believed to leave patients less
vulnerable to opportunistic infections when compared to historical controls
of institutional standard of care. In a clinical proof-of-concept study, T-
Guard(TM) appeared to be well tolerated with strong biological and clinical
responses observed. T-Guard(TM) is currently in clinical Phase 1/2 testing
in Europe for the second-line treatment of steroid-resistant acute GVHD.
The primary endpoint of the study is response rate at 28 days. Other
endpoints include overall survival at 180 days; safety and tolerability are
also being evaluated. Preliminary results from this study showed strong
clinical responses and indicated a substantial improvement over published
institutional historical survival rates, with a well-manageable side effect
profile without severe infusion reactions. T-Guard(TM) has been granted
Orphan Drug Designation in both the EU and US. The Company plans to
initiate a pivotal clinical study in the second half of 2017.

About Graft versus Host Disease (GVHD)
Transplantation of allogeneic (donor-derived) blood stem cells is a widely
accepted medical procedure to restore normal blood cell production
(hematopoiesis) in patients treated for blood or lymphatic cancers or
otherwise suffering from defective blood formation or immunity. Today,
approximately 30,000 patients worldwide receive allogeneic stem cell
transplants every year. Approximately 50% of all blood stem cell transplant
patients develop acute GVHD, a complication where donor-derived T cells
(immune cells) attack the normal tissues of the patient. Half of these
patients do not respond adequately to standard first-line therapy and have
a poor long-term prognosis with severe morbidity and high mortality rates.
This number is expected to grow substantially as the number of patients
receiving high-risk transplants from unrelated donors is expected to double
in the next five years. As of today, there is no approved second-line
treatment available.

About Xenikos B.V.
Xenikos B.V. is developing new, innovative immunotherapies to help restore
patients' health and save lives. It is developing new therapies based on
the action of conjugated antibodies that enables patients suffering from
serious immune diseases or rejection after transplantation to reset their
immune systems quickly and efficiently. Its lead product candidate T-
GuardTM is currently being developed for the second-line treatment of
steroid-resistant acute GVHD. Further information is available at
www.xenikos.com.

For further information, please contact:

Xenikos B.V.
Ypke van Oosterhout
Chief Executive Officer
Telephone: +31 24 3000100
Mobile: +31 6 11017611
E-mail: y.vanoosterhout@xenikos.com

Additional contact information

MC Services AG
Dr. Solveigh Mähler
Telephone: +49 211 529 252 19
E-mail: solveigh.maehler@mc-services.eu

In the U.S.:
Laurie Doyle
Telephone: +1 339 832 0752
E-mail: laurie.doyle@mc-services.eu


---------------------------------------------------------------------------

20.09.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

502931 20.09.2016